Cargando…
Comprehensive analysis of PD‐L1 in non‐small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue
BACKGROUND: The aim of the study was to assess programmed death‐ligand‐1 (PD‐L1) expression in different histological types and gene mutation status of patients with non‐small cell lung cancer (NSCLC). METHODS: A total of 4062 pathology‐confirmed lung cancer patients were retrospectively screened at...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720620/ https://www.ncbi.nlm.nih.gov/pubmed/34841687 http://dx.doi.org/10.1111/1759-7714.14216 |
_version_ | 1784625161999220736 |
---|---|
author | Wang, Chin‐Chou Huang, Kuo‐Tung Chang, Huang‐Chih Tseng, Chia‐Cheng Lai, Chien‐Hao Lan, Jui Liu, Ting‐Ting Huang, Chao‐Cheng Lin, Meng‐Chih |
author_facet | Wang, Chin‐Chou Huang, Kuo‐Tung Chang, Huang‐Chih Tseng, Chia‐Cheng Lai, Chien‐Hao Lan, Jui Liu, Ting‐Ting Huang, Chao‐Cheng Lin, Meng‐Chih |
author_sort | Wang, Chin‐Chou |
collection | PubMed |
description | BACKGROUND: The aim of the study was to assess programmed death‐ligand‐1 (PD‐L1) expression in different histological types and gene mutation status of patients with non‐small cell lung cancer (NSCLC). METHODS: A total of 4062 pathology‐confirmed lung cancer patients were retrospectively screened at Kaohsiung Chang Gung Memorial Hospital from November 2010 to June 2017. There were 699 NSCLC patients with confirmed PD‐L1 expression level retrospectively enrolled for analysis. RESULTS: There was a trend of higher PD‐L1 expression in squamous cell carcinoma and adenosquamous cell carcinoma than in adenocarcinoma (p = 063). Significant higher PD‐L1 expression in EGFR wild‐type was noted (p < 0.001). No significant differences in PD‐L1 expression were found between ALK wild‐ and mutant types, but there seem was a trend of high PD‐L1 level noted in ALK mutation patients (p = 0.069). In EGFR mutation patients, a higher time to treatment failure (TTF) duration was observed in no PD‐L1 expression (p = 0.011). Longer tumor tissue storage time correlated with lower PD‐L1 expression in lung cancer (p < 0.001 for linear trend). CONCLUSIONS: There were a trend or significant differences in PD‐L1 expression between different histological types in NSCLC, different EGFR and ALK status, and different tumor tissue storage time. A higher survival benefit was observed in no PD‐L1 expression than with PD‐L1 expression in adenocarcinoma, EGFR and ALK mutation patients. We recommend that PD‐L1 assay should be performed as early as possible if tissue is available. |
format | Online Article Text |
id | pubmed-8720620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-87206202022-01-07 Comprehensive analysis of PD‐L1 in non‐small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue Wang, Chin‐Chou Huang, Kuo‐Tung Chang, Huang‐Chih Tseng, Chia‐Cheng Lai, Chien‐Hao Lan, Jui Liu, Ting‐Ting Huang, Chao‐Cheng Lin, Meng‐Chih Thorac Cancer Original Articles BACKGROUND: The aim of the study was to assess programmed death‐ligand‐1 (PD‐L1) expression in different histological types and gene mutation status of patients with non‐small cell lung cancer (NSCLC). METHODS: A total of 4062 pathology‐confirmed lung cancer patients were retrospectively screened at Kaohsiung Chang Gung Memorial Hospital from November 2010 to June 2017. There were 699 NSCLC patients with confirmed PD‐L1 expression level retrospectively enrolled for analysis. RESULTS: There was a trend of higher PD‐L1 expression in squamous cell carcinoma and adenosquamous cell carcinoma than in adenocarcinoma (p = 063). Significant higher PD‐L1 expression in EGFR wild‐type was noted (p < 0.001). No significant differences in PD‐L1 expression were found between ALK wild‐ and mutant types, but there seem was a trend of high PD‐L1 level noted in ALK mutation patients (p = 0.069). In EGFR mutation patients, a higher time to treatment failure (TTF) duration was observed in no PD‐L1 expression (p = 0.011). Longer tumor tissue storage time correlated with lower PD‐L1 expression in lung cancer (p < 0.001 for linear trend). CONCLUSIONS: There were a trend or significant differences in PD‐L1 expression between different histological types in NSCLC, different EGFR and ALK status, and different tumor tissue storage time. A higher survival benefit was observed in no PD‐L1 expression than with PD‐L1 expression in adenocarcinoma, EGFR and ALK mutation patients. We recommend that PD‐L1 assay should be performed as early as possible if tissue is available. John Wiley & Sons Australia, Ltd 2021-11-28 2022-01 /pmc/articles/PMC8720620/ /pubmed/34841687 http://dx.doi.org/10.1111/1759-7714.14216 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Wang, Chin‐Chou Huang, Kuo‐Tung Chang, Huang‐Chih Tseng, Chia‐Cheng Lai, Chien‐Hao Lan, Jui Liu, Ting‐Ting Huang, Chao‐Cheng Lin, Meng‐Chih Comprehensive analysis of PD‐L1 in non‐small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue |
title | Comprehensive analysis of PD‐L1 in non‐small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue |
title_full | Comprehensive analysis of PD‐L1 in non‐small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue |
title_fullStr | Comprehensive analysis of PD‐L1 in non‐small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue |
title_full_unstemmed | Comprehensive analysis of PD‐L1 in non‐small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue |
title_short | Comprehensive analysis of PD‐L1 in non‐small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue |
title_sort | comprehensive analysis of pd‐l1 in non‐small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720620/ https://www.ncbi.nlm.nih.gov/pubmed/34841687 http://dx.doi.org/10.1111/1759-7714.14216 |
work_keys_str_mv | AT wangchinchou comprehensiveanalysisofpdl1innonsmallcelllungcancerwithemphasisonsurvivalbenefitimpactofdrivermutationandhistologicaltypesandarchivaltissue AT huangkuotung comprehensiveanalysisofpdl1innonsmallcelllungcancerwithemphasisonsurvivalbenefitimpactofdrivermutationandhistologicaltypesandarchivaltissue AT changhuangchih comprehensiveanalysisofpdl1innonsmallcelllungcancerwithemphasisonsurvivalbenefitimpactofdrivermutationandhistologicaltypesandarchivaltissue AT tsengchiacheng comprehensiveanalysisofpdl1innonsmallcelllungcancerwithemphasisonsurvivalbenefitimpactofdrivermutationandhistologicaltypesandarchivaltissue AT laichienhao comprehensiveanalysisofpdl1innonsmallcelllungcancerwithemphasisonsurvivalbenefitimpactofdrivermutationandhistologicaltypesandarchivaltissue AT lanjui comprehensiveanalysisofpdl1innonsmallcelllungcancerwithemphasisonsurvivalbenefitimpactofdrivermutationandhistologicaltypesandarchivaltissue AT liutingting comprehensiveanalysisofpdl1innonsmallcelllungcancerwithemphasisonsurvivalbenefitimpactofdrivermutationandhistologicaltypesandarchivaltissue AT huangchaocheng comprehensiveanalysisofpdl1innonsmallcelllungcancerwithemphasisonsurvivalbenefitimpactofdrivermutationandhistologicaltypesandarchivaltissue AT linmengchih comprehensiveanalysisofpdl1innonsmallcelllungcancerwithemphasisonsurvivalbenefitimpactofdrivermutationandhistologicaltypesandarchivaltissue |